After a relatively quiet 12 months for mergers and acquisitions in 2017, this year is expected to produce a bumper crop of deals between big pharma and biotech.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.